Wilbur Freeman, DO
Cardiovascular Disease · Peoria, AZNPI 1003293697
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.5%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 34.4% of the total. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $91.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Boston Scientific$15K
- Biosense Webster, Inc.$15K
- Abbott$11K
- Cardiva Medical, Inc.$1K
- Medical Device Business Services, Inc.$784
- plus $2K from 15 others
What the payments were for
- Consulting fees$8,87513%
- Speaking & faculty fees$5001%
- Grants$22,00032%
- Travel & lodging$10,59115%
- Food & beverage$26,68038%
- Education$6921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 124 | $23,835 |
| Boston Scientific | 61 | $15,259 |
| Biosense Webster, Inc. | 330 | $15,065 |
| Abbott | 137 | $11,155 |
| Cardiva Medical, Inc. | 67 | $1,117 |
| Medical Device Business Services, Inc. | 4 | $784 |
| Impulse Dynamics (USA) Inc. | 3 | $514 |
| Cordis US CORP. | 4 | $480 |
| Pfizer | 4 | $227 |
| Sanofi-aventis U.S. LLC | 5 | $188 |
| Edwards Lifesciences | 1 | $182 |
| Elutia, Inc. | 1 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $95 |
| Johnson & Johnson(2 entities) | 4 | $71 |
| Kestra Medical Technology Services, Inc. | 2 | $59 |
| Chiesi USA, Inc. | 3 | $49 |
| Abiomed | 1 | $37 |
| Inari Medical, Inc. | 1 | $35 |
| Amgen | 2 | $23 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$10,985
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$5,000
- EMBLEM MRI S-ICD$5,000
- Micra$2,452
- AVEIR$2,074
- ENSITE PRECISION$1,798
- OPTIMIZER$1,029
- ENSITE$1,019
- GALLANT$989
- COBALT DR MRI SURESCAN$918
- RESOLUTE ONYX$566
- MYNX CONTROL VENOUS$475
- OCTARAY MAPPING CATHETER$453
- Cardiva VASCADE MVP VVCS 6-12F$433
- SYMPLICITY G3$363
- Quadra Assura CRT Defibrillator$351
- QUADRA ASSURA$298
- Watchman$276
- ACCOLADE SR$271
- Thermocool SF$263
How this compares
$69,339 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $94,916 |
| XareltoRivaroxaban | 37 | $34,186 |
| MultaqDronedarone Hcl | 19 | $20,031 |
| Flecainide Acetate | 89 | $5,139 |
| Amiodarone Hcl | 96 | $2,346 |
| Metoprolol Succinate | 84 | $1,409 |
| ClopidogrelClopidogrel Bisulfate | 32 | $422 |
| SotalolSotalol Hcl | 17 | $347 |
| Diltiazem 24hr ErDiltiazem Hcl | 15 | $339 |
| Amlodipine Besylate | 24 | $185 |
| Cephalexin | 28 | $161 |
| Lisinopril | 17 | $144 |
| Furosemide | 45 | $143 |
| Doxycycline Hyclate | 11 | $106 |
| Carvedilol | 17 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $94,91685 claims |
| Johnson & JohnsonXarelto | $71 | $34,18637 claims |
| Sanofi-aventis U.S. LLCMultaq | $188 | $20,03119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Peoria
- Moustafa BannaPeoria$25K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
- Omar WaniFlagstaff$244K
- Robert BurkeScottsdale$207K
- Andrew KaplanMesa$204K
- Tabitha MoePhoenix$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.